WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsStryker Corporation (SYK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 1288989% more annual revenue ($26.30B vs $2.04M). SYK leads profitability with a 13.8% profit margin vs -285.0%. SYK earns a higher WallStSmart Score of 53/100 (C-).

AIDX

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.90

SYK

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 7.5Value: 3.3Quality: 6.5
Piotroski: 2/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

SYKSignificantly Overvalued (-31.3%)

Margin of Safety

-31.3%

Fair Value

$235.85

Current Price

$309.64

$73.79 premium

UndervaluedFair: $235.85Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
36.5%10/10

Revenue surging 36.5% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

SYK3 strengths · Avg: 8.3/10
Market CapQuality
$118.92B9/10

Large-cap with strong market position

Operating MarginProfitability
24.0%8/10

Strong operational efficiency at 24.0%

Free Cash FlowQuality
$1.22B8/10

Generating 1.2B in free cash flow

Areas to Watch

AIDX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.62M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

Free Cash FlowQuality
$-610,8142/10

Negative free cash flow — burning cash

SYK4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
33.3x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

AIDX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.77 — expect wider price swings.

AIDX is growing revenue faster at 36.5% — sustainability is the question.

SYK generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (53/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?